Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene (ALK)-
rearranged non–small-cell lung cancer (ALK-positive NSCLC), initial disease progression …

Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–
rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience …

Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …

8062 Background: Brigatinib is an investigational oral tyrosine kinase inhibitor with
preclinical activity against rearranged ALK and clinically identified crizotinib-resistant …

Introduction We report updated data from a phase 2 randomized study evaluating brigatinib
in crizotinib-refractory anaplastic lymphoma kinase–positive NSCLC. Methods Patients were …

Background Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic
drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational …

PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality …

7514 Background: The anaplastic lymphoma kinase (ALK) fusion gene is a key oncogenic
driver in a subset of NSCLC patients (pts). Crizotinib is a potent, selective, ATP-competitive …

To date, no head-to-head trials have compared the efficacy of brigatinib and alectinib
against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor …

Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged
non–small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain …